(Reuters) - Mylan NV will buy global marketing rights to an experimental multiple sclerosis treatment from Israel's Mapi Pharma, aiming to strengthen its position in the market for MS drugs and counter falling sales of its emergency allergy shot EpiPen. (Source: Reuters: Health)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.



Read full article on medworm.com